Brief: Kintor Pharmaceutical Says Results Of Kx-826 Phase III Clinical Trial In China
27/11/2023 01:24
Nov 27 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* RESULTS OF KX-826 PHASE III CLINICAL TRIAL FOR TREATMENT
OF MALE
AGA IN CHINA
* RESULTS SHOWED OVERALL SAFETY OF TRIAL WAS GOOD, WITH
KX-826
DEMONSTRATING EXCELLENT SAFETY PROFILE
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint